Edison Investment Research - SCANDION ONCOLOGY A/S (SCOL) Scandion Oncology - An active quarter with AML plans in the mix

Report

Edison Investment Research

Sean Conroy

Scandion Oncology - An active quarter with AML plans in the mix

Q123 has been an active quarter for Scandion Oncology with completion of the Phase 1b PANTAX (dose-finding) study and management’s decision to expand the scope of SCO-101 into acute myeloid leukaemia (AML). With many upcoming catalysts, including an update on AML preclinical work in H223, top-line results for CORIST part 3 in H223, and full top-line data for PANTAX by H124, if favourable, we expect material progression of the company’s pipeline. Scandion reported an operating loss of DKK12.0m in Q123 (vs DKK16.3m in Q122) mainly due lower R&D expenses, reflecting the impact of cost control measures announced by management in H222. After updating the net cash position and incorporating the impact of foreign exchange, our valuation of Scandion stands at SEK240.0m or SEK5.9/share (vs SEK238.2m or SEK5.8/share previously).

30/05/2023 1 EN

Underlying

SCANDION ONCOLOGY A/S

Scandion Oncology A/S. Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.

See profile

DK0061031895 Denmark

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Scandion Oncology - PANTAX Phase I trial meets primary endpoint

Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the company’s lead asset, as an add-on therapy for patients with advanced pancreatic cancer (PC). SCO-101, in combination with the chemotherapy agents gemcitabine and nab-paclitaxel, demonstrated a favourable safety and tolerability profile and a maximum tolerated dose (MTD) was established at 200mg for six consecutive days every two weeks. Management has communicated that a more detailed analysis on the full data will be conducted in due course, b...

April 3, 2023 April 3, 2023 1 EN

Edison Investment Research

Scandion Oncology - Expanding SCO-101 into AML

In the recent management conference call to summarise the FY22 results, Scandion Oncology announced plans to expand SCO-101, its lead asset, into acute myeloid leukaemia (AML). The company plans to share certain details on the preclinical data package in H223, which we view as a significant catalyst, provided the data continue to be supportive. SCO-101 is also progressing as planned in the Phase II CORIST trial in metastatic colorectal cancer (mCRC), with readouts expected in Q323, and in the Phase Ib PANTAX trial in pancreatic cancer (PC), with readouts expected in H123.

March 29, 2023 March 29, 2023 1 EN

The Pebble Group - Two distinct businesses in one

The Pebble Group’s AGM update confirms that trading is in line with FY24 expectations, with attractive opportunities for its two distinct businesses in the large, fragmented promotional products sector. Facilisgroup is a SaaS business, helping North American distributors to optimise their operations, with access to an approved supplier roster. Brand Addition services global brands’ needs for branded product for in-house and external programmes. The well-publicised dip in tech sector marketing spend was a key factor in Pebble’s Q423 outlook revision. Both segments are now well placed to benefit...

19h / 19m 19h / 19m 1 EN

Richard Williamson

Richard Williamson

MotorK - Strong pipeline and cash target reaffirmed

MotorK’s FY23 revenue growth was robust across most regions, with slow growth regions gaining momentum. Q124 revenue fell slightly year-on-year due to delayed delivery contracts, but these are expected to contribute to Q2 sales. Revenue quality improved, with software-as-a-service (SaaS) recurring revenue rising as a share of group revenue in FY23. M&A continues to play a pivotal role in unlocking opportunities across MotorK's markets, providing potential average contract value (ACV) expansion from customers migrating to the platform. While personnel investments for growth swung EBITDA to a lo...

21h / 5m 21h / 5m 1 EN

Sean Conroy

Sean Conroy

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Newron Pharmaceuticals has shared positive top-line data for its evenamide programme from its potentially pivotal Phase II/III trial (study 008A) in patients with poorly managed schizophrenia on current antipsychotic therapy, but not considered treatment-resistant. The trial met its primary endpoint of improvement on the Positive and Negative Syndrome Scale (PANSS) score from baseline, and the key secondary endpoint of improvement on the Clinical Global Impression of Severity (CGI-S) scale. Statistical significance was met in both, consolidating the already strong results from the Phase II tri...

21h / 17m 21h / 17m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Scandion Oncology - An active quarter with AML plans in the mix

Scandion Oncology - PANTAX Phase I trial meets primary endpoint

Scandion Oncology - Expanding SCO-101 into AML

The Pebble Group - Two distinct businesses in one

MotorK - Strong pipeline and cash target reaffirmed

Newron Pharmaceuticals - Evenamide notches up another win (study 008A)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe